0.1900GBp-7.32%Mkt Cap: 4.96M GBpP/E: —Last update: 2026-06-01
Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The compan…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap4.96M GBp
Enterprise Value3.20M GBp
Revenue (TTM)—
Gross Profit0 GBp
Net Income (TTM)-652.59K GBp
Revenue/Share—
Last Price0.1900 GBp
Fiscal Year EndSep 2025
MR QuarterSep 2025
Employees3
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-5.06
EV/Revenue—
P/S—
P/B—
EPS (TTM)0.00
EPS (Forward)—
52W Range
0.071025% of range0.5550
52W High0.5550 GBp
52W Low0.0710 GBp
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-86.44%
ROA-64.05%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-614.61K GBp
CapEx (TTM)—
FCF Margin—
FCF Yield-7.56%
Net Debt-97.55K GBp
Net Debt/EBITDA0.15
Balance Sheet
Debt/Equity—
Current Ratio0.52
Quick Ratio0.43
Book Value/Sh0.0000 GBp
Cash/Share0.0000 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBp
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.2.61B
Float1.92B
Insiders5.37%
Institutions0.07%
Technical
SMA 500.1772 (+7.2%)
SMA 2000.2234 (-15.0%)
Beta1.50
S&P 52W Chg27.94%
Avg Vol (30d)31.15M
Avg Vol (10d)19.32M
Technical Indicators
RSI (14)63.0
MACD-0.0016
MACD Signal-0.0037
MACD Hist.+0.0020
BB Upper0.2042 GBp
BB Middle0.1765 GBp
BB Lower0.1488 GBp
BB Width31.43%
ATR (14)0.0246 GBp
Vol Ratio (20d)8.87x